Natera (NTRA) Financial Analysis & Valuation | Quarter Chart
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single... more
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwid... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $52.90B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Steven Leonard Chapman |
| IPO Date | 2015-07-01 | CAGR | 47.89% |
| Employees | 6,138 | Website | www.natera.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.03% | Total Yield | -0.03% |
NTRA chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $44.80B | P/E | -279.84 | Forward P/E | -3589.45 | PEG | — |
| P/S | 31.77 | P/B | 47.15 | P/CF | 376.45 | P/FCF | 1197.83 |
| Sales | $2.71B | Sales 1Y | 37.82% | Sales 3Y | 190.76% | Sales 5Y | 436.2% |
| EPS | $-1.32 | EPS 1Y | -28.8% | EPS 3Y | -72.24% | EPS 5Y | -63.44% |
| Sales QoQ | 8.05% | EPS QoQ | -21.67% | Sales QoQ Avg | 8.36% | EPS QoQ Avg | -115.32% |
| Gross Margin | 65.3% | Operating Margin | -10.7% | Profit Margin | -7.11% | ROCE | -13.77% |
| ROA | -7% | ROE | -12% | Altman Z Score | 31.81 | Piotroski Score | 3 |
| Current Ratio | 3 | Quick Ratio | 2.85 | Cash Ratio | 1.97 | Op. CF Ratio | 0.1 |
| Debt/Equity | 0.12 | Debt/Assets | 0.08 | Lt Debt/Equity | 0.08 | Lt Debt/Cap. | 0.07 |
| Intrst Cov. | -29.04 | Inventory Turnover | 11.69 | Asset Turnover | 1.02 | Receivables Turnover | 6.42 |
| Enterprise Value | $44.80B | P/E Ratio | -279.84 |
| Forward P/E | -3589.45 | PEG Ratio | — |
| P/S Ratio | 31.77 | P/B Ratio | 47.15 |
| P/CF Ratio | 376.45 | P/FCF Ratio | 1197.83 |
| EPS | $-1.32 | EPS Growth 1Y | -28.8% |
| EPS Growth 3Y | -72.24% | EPS Growth 5Y | -63.44% |
| Revenue Growth 1Y | 37.82% | Gross Margin | 65.3% |
| Operating Margin | -10.7% | Profit Margin | -7.11% |
| ROE | -12% | ROA | -7% |
| ROCE | -13.77% | Current Ratio | 3 |
| Quick Ratio | 2.85 | Cash Ratio | 1.97 |
| Debt/Equity | 0.12 | Interest Coverage | -29.04 |
| Altman Z Score | 31.81 | Piotroski Score | 3 |
Natera (NTRA) valuation & financials
Natera (NTRA) has a market capitalization of $52.90B and trades at a price-to-earnings ratio of -279.8. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Natera's revenue grew +37.8% over the last year.
Natera's next earnings report is scheduled for November 5, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.22. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)